Abstract:This study investigated the molecular mechanism of long intergenic non-protein coding RNA 1605 (LINC01605) in the process of tumor growth and liver metastasis of pancreatic ductal adenocarcinoma (PDAC). LINC01605 was filtered out with specificity through TCGA datasets (related to DFS) and our RNA-sequencing data of PDAC tissue samples from Renji Hospital. The expression level and clinical relevance of LINC01605 were then verified in clinical cohorts and samples by immunohistochemical staining assay and survival analysis. Loss- and gain-of-function experiments were performed to estimate the regulatory effects of LINC01605 in vitro. RNA-seq of LINC01605-knockdown PDAC cells and subsequent inhibitor-based cellular function, western blotting, immunofluorescence and rescue experiments were conducted to explore the mechanisms by which LINC01605 regulates the behaviors of PDAC tumor cells. Subcutaneous xenograft models and intrasplenic liver metastasis models were employed to study its role in PDAC tumor growth and liver metastasis in vivo. LINC01605 expression is upregulated in both PDAC primary tumor and liver metastasis tissues and correlates with poor clinical prognosis. Loss and gain of function experiments in cells demonstrated that LINC01605 promotes the proliferation and migration of PDAC cells in vitro. In subsequent verification experiments, we found that LINC01605 contributes to PDAC progression through cholesterol metabolism regulation in a LIN28B-interacting manner by activating the mTOR signaling pathway. Furthermore, the animal models showed that LINC01605 facilitates the proliferation and metastatic invasion of PDAC cells in vivo. Our results indicate that the upregulated lncRNA LINC01605 promotes PDAC tumor cell proliferation and migration by regulating cholesterol metabolism via activation of the mTOR signaling pathway in a LIN28B-interacting manner. These findings provide new insight into the role of LINC01605 in PDAC tumor growth and liver metastasis as well as its value for clinical approaches as a metabolic therapeutic target in PDAC.

LINC00941 Promotes Glycolysis in Pancreatic Cancer by Modulating the Hippo Pathway

Linc00901 Regulates Glucose Metabolism In Pancreatic Cancer.

Abstract 2389: LINC00901 Regulates Glucose Metabolism in Pancreatic Cancer

LINC00346 Promotes Pancreatic Cancer Progression Through the CTCF-mediated Myc Transcription

Abstract 1821: LINC00346 Regulates C-Myc Transcriptional Activity Through CTCF in Pancreatic Cancer

LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling

Oncogenic lncRNA LINC00973 promotes Warburg effect by enhancing LDHA enzyme activity

LncRNA Wires Up Hippo and Hedgehog Signaling to Reprogramme Glucose Metabolism

Deciphering the Genomic and Lncrna Landscapes of Aerobic Glycolysis Identifies Potential Therapeutic Targets in Pancreatic Cancer.

LINC01137 Facilitates Pancreatic Cancer Stemness Via the Mir-7155-5p/klf12/akt Axis

Tumor-derived Exosomal Long Noncoding RNA LINC01133, Regulated by Periostin, Contributes to Pancreatic Ductal Adenocarcinoma Epithelial-Mesenchymal Transition Through the Wnt/β-catenin Pathway by Silencing AXIN2.

LINC00908 promotes malignant progression and glycolysis in lung adenocarcinoma via interactions with DDX54 and RFX2

LINC00460 Promotes Pancreatic Cancer Progression by Sponging Mir‐491‐5p

LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis

Genome-wide RNA-sequencing dataset reveals the prognostic value and potential molecular mechanisms of lncRNA in non-homologous end joining pathway 1 in early stage Pancreatic Ductal Adenocarcinoma

Role of long intergenic non-protein coding RNA 00152 in pancreatic cancer glycolysis via the manipulation of the microRNA-185-5p/Krüppel-like factor 7 axis

The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway

LINC00665 promotes glycolysis in lung adenocarcinoma cells via the let-7c-5p/HMMR axis

LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability

Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma

Epigenetic Silencing of LncRNA LINC00261 Promotes C-Myc-mediated Aerobic Glycolysis by Regulating Mir-222-3p/hipk2/erk Axis and Sequestering IGF2BP1